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Wrch-1 is a Rho family GTPase that shares strong sequence and
functional similarity with Cdc42. Like Cdc42,Wrch-1 can promote
anchorage-independent growth transformation. We determined
that activatedWrch-1 also promoted anchorage-dependent growth
transformation of NIH 3T3 fibroblasts. Wrch-1 contains a distinct
carboxyl-terminal extension not found in Cdc42, suggesting poten-
tial differences in subcellular location and function.Consistentwith
this, we found that Wrch-1 associated extensively with plasma
membrane and endosomes, rather than with cytosol and perinu-
clear membranes like Cdc42. Like Cdc42, Wrch-1 terminates in a
CAAX tetrapeptide (where C is cysteine, A is aliphatic amino acid,
andX is any amino acid)motif (CCFV), suggesting thatWrch-1may
be prenylated similarly to Cdc42. Most surprisingly, unlike Cdc42,
Wrch-1didnot incorporate isoprenoidmoieties, andWrch-1mem-
brane localization was not altered by inhibitors of protein prenyla-
tion. Instead, we showed that Wrch-1 is modified by the fatty acid
palmitate, and pharmacologic inhibition of protein palmitoylation
caused mislocalization of Wrch-1. Most interestingly, mutation of
the second cysteine of the CCFVmotif (CCFV > CSFV), but not the
first, abrogated both Wrch-1 membrane localization and transfor-
mation. These results suggest that Wrch-1 membrane association,
subcellular localization, and biological activity are mediated by a
novel membrane-targeting mechanism distinct from that of Cdc42
and other isoprenylated Rho family GTPases.
The Rho family of Ras-related small GTPases is a functionally diverse
group of proteins that are best known for their roles in regulation of
actin cytoskeleton organization, cell polarity, cell adhesion, vesicular
trafficking, transcriptional regulation, and cell cycle progression (1, 2).
Of the 22 known human Rho GTPases, RhoA, Rac1, and Cdc42 are the
most extensively characterized family members (3).
Like Ras, Rho proteins cycle between an inactive GDP-bound state
and an active GTP-bound state (2, 4, 5). Guanine nucleotide exchange
factors activate Rho proteins by promoting GDP dissociation in
exchange for GTP (6, 7), whereas GTPase-activating proteins down-
regulate Rho protein function by stimulating their intrinsic GTPase
activity to hydrolyze GTP to GDP (8). A third regulatory class of pro-
teins includes the Rho guanine nucleotide dissociation inhibitors
(RhoGDIs)4 that bind the carboxyl terminus of Rho GTPases and
sequester them in the cytosol (9, 10). Missense mutations within the
switch regions of Rho proteins lock them in aGTP-bound conformation
and render these proteins GTPase-deficient and constitutively acti-
vated. Activated forms of someRho familyGTPases cause growth trans-
formation of NIH 3T3 mouse fibroblasts, and aberrant activity of both
regulatory proteins and effectors of the Rho signaling pathways have
been linked to human cancers (11–14).
Wrch-1 (Wnt-regulated Cdc42 homolog-1) is a novel member of the
Rho subfamily, whose transcription is up-regulated in Wnt-1 transfor-
mation of mouse mammary epithelial cells (15). Like many other Rho
family members, Wrch-1 activation is regulated by its nucleotide state,
and a single missense mutation at residue 107 (analogous to Q61L acti-
vating mutation in Cdc42) rendered Wrch-1 more active in signaling
(15). Ectopic expression of a constitutively active form ofWrch-1(107L)
caused a Wnt1-like change in the cellular morphology of mammary
epithelial cells, suggesting a contribution for Wrch-1 in Wnt transfor-
mation (15). Additionally, like other Rho family proteins, Wrch-1 acti-
vation can promote growth transformation (16).
The correct subcellular localization and function of Ras and Rho fam-
ily members are dictated by post-translational modification of the car-
boxyl-terminal hypervariable domain, including the last four amino
acids known as the CAAX motif (17, 18). The canonical CAAX motif
consists of a cysteine residue, two aliphatic residues (AA), and at the last
position any amino acid (X). The conserved cysteine residue serves as
the site for post-translational modification by either farnesyltransferase
(FTase) or geranylgeranyltransferase I (GGTase I), which irreversibly
attaches an isoprenoid moiety (19). Although CAAX-signaled prenyla-
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tion is necessary (20–25), a second targeting signal immediately
upstream of the CAAX motif is also required for proper membrane
association and subcellular localization. Some small GTPases, such as
H-Ras, N-Ras, and the Cdc42-related protein TC10, are covalently
modified by addition of a palmitoyl fatty acid on cysteine residues,
whereas others, such as K-Ras4B and Cdc42, contain several basic res-
idues that serve as their second targeting signal (18, 23, 26). Finally,
additional carboxyl-terminal sequences provide further specificity in
targeting Ras and Rho GTPases to distinct plasmamembrane microdo-
mains or to endomembrane compartments. Thus, functionally highly
related Rho GTPase isoforms (e.g. RhoA, RhoB, and RhoC), by virtue of
divergent carboxyl-terminal sequences and modifications, can exhibit
strikingly different biological functions dependent on distinct subcellu-
lar locations (22, 27, 28).
Although Wrch-1 has been shown to localize to plasma membrane
and internal membranes (15, 29), the role of the carboxyl terminus in
mediating Wrch-1 biological function has not been determined. Like
Cdc42,Wrch-1 induces actin reorganization and formation of filopodia
and causes activation of the PAK and c-JunNH2-terminal kinase serine/
threonine kinases (15). However, Wrch-1 contains amino-terminal
sequences not found in Cdc42, and we and others recently showed that
this amino-terminal extension serves as a negative modulator of
Wrch-1 effector interaction (16, 30). In addition, Wrch-1 and Cdc42
differ considerably at their carboxyl termini, sharing only 25% sequence
identity. Furthermore,Wrch-1 has an extended carboxyl terminus end-
ing in an unusual CAAX sequence (CCFV) not characteristic of known
substrates for farnesyl- and geranylgeranyltransferases (31, 32). There-
fore, in the present study we assessed the mechanism and role of the
unique carboxyl terminus in regulation of Wrch-1 function. As with
Cdc42, we found that Wrch-1 activation caused anchorage-dependent
growth transformation of NIH 3T3 cells. However, although the car-
boxyl terminus was critical for Wrch-1 subcellular localization and
transforming activity, Wrch-1 function was dependent not on modifi-
cation by prenylation but on modification by palmitoylation. Thus,
although Wrch-1 and Cdc42 share significant functional properties,
they exhibit considerable divergence in lipid modifications and subcel-
lular distribution and, consequently, may have divergent roles in cell
physiology.
EXPERIMENTAL PROCEDURES
Molecular Constructs—pcDNA3 expression constructs encoding
wild type (WT) and GTPase-deficient (Q107L) human Wrch-1 was
obtained from Dr. A. Levine (15). PCR-mediated DNA amplification
was used to introduce 5 and 3 BamHI sites flanking Wrch-1(WT) for
subcloning into various epitope-tagged expression vector constructs.
To create other constitutively activatedmutants ofWrch-1, a glutamate
to leucine mutation was generated at residue 107 using the Quick-
Change site-directed mutagenesis kit (Stratagene, La Jolla, CA) accord-
ing to the manufacturer’s instructions. Site-directed mutagenesis was
also used to create the carboxyl-terminal CCFV motif mutants by
changing cysteine residues at positions 255 and 256 to generate
CCFV  SCFV (C255S), CCFV  CSFV (C256S), and CCFV  SSFV
(C255S and C256S) point mutants in the activated Wrch-1(Q107L)
background. To generate glutathione S-transferase (GST), green fluo-
rescence protein (GFP), and hemagglutinin (HA) epitope-tagged
Wrch-1 proteins for prenylation, transformation, and localization
assays, Wrch-1 coding regions were digested with BamHI and ligated
into the BamHI site of pGEX-2T multiple cloning site, the 5 BglII and 3
BamHI sites of thepEGFP-C1 (multiple cloning site), and theBamHI site of
pCGN-hygro, respectively (33).All sequenceswere verified by theGenome
Analysis Facility at the University of North Carolina, Chapel Hill.
Cell Culture and Transfections—NIH 3T3 mouse fibroblasts were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% calf serum (Invitrogen) and 1% penicillin/streptomy-
cin (Invitrogen). Stable NIH cell lines were created by transfection of
pCGN-wrch-1 constructs with FuGENE 6 (Roche Applied Science) per
the manufacturer’s instructions. After 48 h, cells were split into DMEM
containing 200 g/ml hygromycin B (Roche Applied Science) and
maintained in antibiotic selection until colonies formed.Colonies (50)
were pooled for use in soft agar assays.
Transformation Assays—For focus forming assays, NIH 3T3 cells
were seeded at 2  105 cells per 60-mm dish. The following day, cells
were transiently cotransfected for 4 h with HA-tagged pCGN con-
structs encoding empty vector, activatedWrch-1(107L)-CCFV, -SCFV,
-CSFV, or -SSFV carboxyl-terminal mutants along with pZIP-
NeoSV(x)1 empty vector or pZIP-Raf22W (encoding an amino-termi-
nal truncated and constitutively activated variant of human Raf-1), by
calcium phosphate precipitation as described previously (25). After
20–24 days, dishes were washed with 1 phosphate-buffered saline
(PBS), fixed with 3:1 (v/v) methanol/acetic acid, and stained with 0.4%
crystal violet solution in 20% ethanol. Non-Raf foci of transformed cells
(see text) were counted, and the average number of foci found on dupli-
cate sets of dishes was then calculated.
For soft agar assays, NIH 3T3 cells stably expressing HA epitope-
tagged pCGN constructs of either empty vector, activated Wrch-
1(107L)-CCFV, -SCFV, -CSFV, or -SSFV were suspended in DMEM
containing 10% calf serum, 1% penicillin/streptomycin, and 0.4% agar
(BD Biosciences) at 5  104 cells per 35-mm dish. The single cell sus-
pensions were layered on top of 0.6% agar in DMEM. Colonies that
formed after 14–21 days were stained with 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide, and the average number of colo-
nies on triplicate dishes was calculated.
Live Cell Imaging—Toanalyze subcellular localization and lipidmod-
ifications of Wrch-1 proteins, NIH 3T3 cells were seeded onto glass
coverslips in 35-mm dishes. The following day, cells were placed in
DMEM supplemented with either Me2SO vehicle, 10 M FTI-2153, 10
M GGTI-2166, 10 M FTI-2153  GGTI-2166, 20 M compactin
(Sigma), or 150 M 2-bromopalmitate (2-BP, Sigma) immediately prior
to transient transfection with FUGENE, of GFP-tagged pEGFP con-
structs containing Wrch-1-tail (13 amino acids), Wrch-1(Q107L)-
CCFV, -SSFV, Cdc42-tail (20 amino acids), Cdc42(61L), H-Ras(61L),
K-Ras4B(12V), or Rab5. FTI-2153 and GGTI-2166 were generous gifts
from Andrew D. Hamilton (Yale University) and Saı̈d M. Sebti (H. Lee
Moffitt Cancer Center and Research Institute, University of South Flor-
ida). After 24–48 h, live cell images were captured on either an epifluo-
rescent Zeiss Axioskop or Zeiss 510 LSM confocal microscope (Zeiss,
Thornwood, NY) usingMetaMorph imaging software (Universal Imag-
ing Corp., Downington, PA) or LSM 5 Image browser software (Zeiss,
Thornwood, NY).
To visualize localization of GFP-tagged Wrch-1(Q107L) to early
endosomes, NIH 3T3 fibroblasts were transiently transfected with
pEGFP-Wrch-1(Q107L). 24 h later, cells were serum-starved for 30min
with DMEM, rinsed in 1 PBS, and then treated with DMEM contain-
ing 30 g/ml Texas Red-conjugated transferrin (Molecular Probes).
After 10 min of incubation, cells were rinsed in 1 PBS, placed in
DMEM, and analyzed for GFP-tagged Wrch-1(Q107L) localization
using a fluorescein isothiocyanate (FITC) bandpass filter and Texas
Red-conjugated transferrin using a Texas Red (TRITC) bandpass filter.
Colocalization of GFP-tagged Wrch-1(Q107L) and Texas Red-con-
jugated transferrin images was analyzed using MetaMorph imaging
software.
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Immunofluorescence—NIH 3T3 cells were seeded onto glass cover-
slips in 35-mmdishes. After 24 h, cells were transfectedwithHA-tagged
pCGN-wrch-1(107L) constructs using FuGENE 6. After 24 h, cells were
fixed with 3.7% formaldehyde in PBS and permeabilized with 0.5% Tri-
ton X-100 in Tris-buffered saline (TBS). Cells were then incubated with
anti-HA antibody (Covance) for 1 h at room temperature. After three
washes in 0.1% Triton X-100 in TBS, cells were incubated with Alexa
Fluor 488-conjugated secondary antibody for 30 min (Molecular
Probes) and washed three times with 0.1% Triton X-100 in TBS. Cov-
erslips were mounted onto glass microslides with Vectashield Hardset
mounting medium (Vector Laboratories, Burlingame, CA) and ana-
lyzed on the fluorescent microscope as described above.
Metabolic Labeling—NIH 3T3 cells were seeded at 2  105 cells per
60-mm dish and transiently transfected with HA epitope-tagged pCGN
constructs containing Wrch-1(107L) CCFV, -SCFV, -CSFV, -SSFV,
H-Ras(61L), K-Ras(12V), or empty vector with FuGENE 6. After 48 h,
cells were labeled for 4 h with 1 mCi/ml [3H]palmitate (American
Radiochemical Inc.) in DMEM containing 5 mM sodium pyruvate, 4
nonessential amino acids, 1% glutamine, 20 mM HEPES, pH 7.2, 25
g/ml cycloheximide, and 10% calf serum. Cells were then rinsed twice
with TBS and lysed in Hi-SDS RIPA buffer (1 M Tris, pH 7.0, 5 M NaCl,
10% SDS, 1% sodium deoxycholate, 1% Nonidet P-40, 0.2 M Pefabloc,
0.05–0.10 trypsin inhibitory units/ml aprotinin). For immunoprecipi-
tation, lysates were incubated for 1 h with anti-HA antibody and then
incubated for 30 min with protein A/G beads (Santa Cruz Biotechnol-
ogy). The immunoprecipitates were washed, resuspended in nonreduc-
ing protein sample buffer (10% SDS, 1 M Tris-HCl, pH 6.8, 25% sucrose,
0.01% bromphenol blue), resolved on SDS-PAGE, and transferred to
polyvinylidene difluoridemembrane (Immobilon-P,Millipore, Bedford,
MA). Membranes were then sprayed with EN3HANCE (PerkinElmer
Life Sciences) and exposed to film at 80 °C for 90 days. To detect total
amount of immunoprecipitated protein available for labeling, mem-
branes were blocked in 5% nonfat dry milk, and immunoprecipitated
proteins were detected with primary mouse anti-HA antibody followed
by anti-mouse IgG-horseradish peroxidase (HRP)-conjugated antibody
(Amersham Biosciences). Membranes were incubated in SuperSignal
West Dura extended duration substrate (Pierce) and developed on film.
Biotin (Btn)-BMCC Fatty Acyl Thioester Bond Labeling—To label
Wrch-1 cysteine-palmitate thioester bonds, a modified version of a
method described recently for detecting protein palmitoylation was
used (34). Briefly, human embryonic kidney 293 cells transiently
expressing GFP-tagged Wrch-1 proteins were lysed in BMCC lysis
buffer (150mMNaCl, 5mMEDTA, 50mMTris, pH7.4, 0.02%NaN3, and
2%TritonX-100) containing Complete protease inhibitor tablet (Roche
Applied Science). Whole cell lysates were cleared, and protein concen-
trations were normalized using DC Lowry protein assay (Bio-Rad). For
immunoprecipitation, protein lysates were pre-cleared with protein
A/G-conjugated agarose beads (Santa Cruz Biotechnology, Santa Cruz,
CA), incubated with anti-GFP antibody (Clontech) for 2 h, and then
incubated for 1 h with protein A/G-conjugated beads (Santa Cruz Bio-
technology). Immunoprecipitates were washed, resuspended in 50 mM
N-ethylmaleimide (Sigma) in BMCC lysis buffer to block free sulfhy-
dryl groups, and incubated for 48 h. Immunoprecipitates were washed,
treated for 1 h with 1 M hydroxylamine (Sigma) to hydrolyze any cys-
teine-palmitate thioester bonds, washed, and then treated with 1 M
Btn-BMCC (Pierce) in 50 mM Tris, pH 7.0, for 2 h to label cleaved
thioester bonds. Immunoprecipitates were washed, resuspended in
nonreducing protein sample buffer (10% SDS, 1MTris-HCl, pH6.8, 25%
sucrose, 0.01% bromphenol blue), resolved on SDS-PAGE, and trans-
ferred to polyvinylidene difluoridemembrane (Immobilon-P,Millipore,
Bedford,MA).Membraneswere probedwith streptavidin-HRP (Pierce)
to detect incorporation of Btn-BMCC, incubated in SuperSignal West
Dura extended duration substrate (Pierce), and developed on film.
Purified Protein Preparation and in Vitro Prenylation Assay—Re-
combinant GST-tagged proteins were produced from Escherichia coli
BL21 strain as described previously (16). Protein induction was con-
firmed by SDS-PAGE and Coomassie staining.
For isoprenylation of purified proteins, 5 g of each purified protein
was added to the prenylation reaction mixture containing 30 g of
bovine brain high speed supernatant and 1 M [3H]farnesylpyrophos-
phate (FPP) or [3H]geranylgeranylpyrophosphate (GGPP) (8–10
Ci/mmol; American Radiochemical, Inc.). Reaction mixture was incu-
bated for 30 min at 30 °C. Reaction was stopped with SDS protein sam-
ple buffer. Samples were boiled briefly, run on 4–20% SDS-PAGE, pre-
pared for fluorography, and exposed to preflashed film for 4 days.
Western Blot Analysis—NIH 3T3 cells transiently expressing GFP-
tagged or HA-tagged Wrch-1 proteins were lysed in 1% Triton X-100
lysis buffer containing protease inhibitors (5 g/ml aprotinin, 10 M
leupeptin, 20 nM -glycerophosphate, 12 mM p-nitrophenyl phosphate,
0.5 mM Pefabloc, and 0.1 mM sodium vanadate) or magnesium lysis
buffer (25 mM HEPES, 150 mM NaCl, 1% Nonidet P-40, 0.25% sodium
deoxycholate, 10% glycerol, 10 mM MgCl2, and 1 mM EDTA, pH 8.0,
containing Complete protease inhibitor tablet). Whole cell lysates were
cleared, and protein concentration was determined using DC Lowry
protein assay. Fifteen g of protein lysates were prepared in sample
buffer, resolved on SDS-PAGE, and transferred to Immobilon-P mem-
brane.Membranes were then blocked in 5% nonfat drymilk and probed
for HA-tagged Wrch-1 proteins using mouse anti-HA antibody, for
-actin as a loading control using mouse anti--actin (Sigma), for
endogenous phosphorylated PAK using rabbit anti-phospho-PAK1
(Ser-144)/PAK2 (Ser-141), for total endogenous PAK using rabbit anti-
PAK1/2/3, or for GFP-tagged proteins using mouse anti-GFP antibody
(Clontech), followed by anti-mouse HRP-conjugated antibody or anti-
rabbit HRP-conjugated antibody and SuperSignal West Dura extended
duration substrate as above.
RESULTS
The Carboxyl-terminal Nine Residues of Wrch-1 Promote a Subcellu-
lar Distribution Distinct from That Seen for Cdc42—As shown in Fig.
1A, the carboxyl termini of Wrch-1 and Cdc42 exhibit sequence differ-
ences that may result in different functional roles for Wrch-1. First,
Wrch-1 terminates in an atypical CAAX motif. Second, Wrch-1 con-
tains an additional 21 residues that have no counterpart in the Cdc42
carboxyl terminus. To determine the role of Wrch-1 carboxyl-terminal
sequences in dictating Wrch-1 membrane association and subcellular
location, and to compare these properties with those of Cdc42, we
expressed GFP-tagged Wrch-1 and Cdc42 in NIH 3T3 mouse fibro-
blasts and performed live cell imaging analyses (Fig. 1B). Whereas GFP
alone localized to the cytosol and prominently in the nucleus, both
GFP-Cdc42 andGFP-Wrch-1were excluded from the nucleus. Consist-
ent with previous observations (18), we detected Cdc42 localization
strongly in the cytosol, with its predominant membrane staining in the
perinuclear region. Wrch-1, however, distributed mainly to the plasma
membrane and to internal membranes reminiscent of endosomes and
polarized, perinuclear Golgi, demonstrating an only partially overlap-
ping localization pattern with that of Cdc42 (Fig. 1B) (15, 29).
We next wanted to determine which of the unique carboxyl-terminal
sequences of Wrch-1 were sufficient to dictate its unique localization.
Philips and colleagues (18) demonstrated previously that the carboxyl-
terminal CAAX- and hypervariable domain-containing 20 amino acids
of Cdc42 and other Rho family GTPases were sufficient to determine
their membrane targeting. As described previously, a GFP fusion pro-
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tein terminating in the 20 carboxyl-terminal residues of Cdc42 exhib-
ited the same subcellular distribution as authentic Cdc42 (data not
shown) (18, 22). Despite the extended length of the Wrch-1 carboxyl
terminus, we found that even fewer residues were sufficient for authen-
ticWrch-1 localization, as a GFP fusion protein terminating in the nine
most carboxyl-terminal residues of Wrch-1 displayed the same plasma
membrane and endosomal localization as authentic Wrch-1 (Fig. 1B).
To confirm that the internal membrane structures were indeed endo-
somes, we compared directly the localization ofGFP-Wrch-1 andTexas
Red-transferrin, which marks early endosomes. As shown in Fig. 1C,
merging these images demonstrated that Wrch-1 on internal mem-
branes colocalizes with transferrin. Thus, although Wrch-1 and Cdc42
regulate similar downstream effector functions (15, 29), they exhibit
significant differences in their subcellular distribution.
Wrch-1 Membrane Localization Is Not Dependent Upon a CAAX
Motif—By analogy to Cdc42 and other CAAX-terminating small
GTPases, the existence of a putative CAAX motif (CCFV) in Wrch-1
suggested that the cysteine at residue 255 (CCFV) is likely to be a target
for prenylation and critical for membrane localization. To evaluate this
possibility, we generated HA-tagged Wrch-1 proteins with missense
mutations in the CAAX motif. Cysteine to serine substitutions of the
cysteine residue of the CAAXmotif abolishes the prenylation of Ras and
Rho GTPases, resulting in cytosolic and inactive proteins (20–23, 25).
Therefore, we generated the analogous mutant of Wrch-1 (C255S,
SCFV).Most surprisingly, this mutant did not localize exclusively to the
cytosol as seen in similarly mutated Ras and Rho GTPases (20–24).
Instead, it exhibited similar subcellular localization as wild typeWrch-1
(Fig. 2). However, it did show reduced asymmetrical “Golgi-like” local-
ization near the nucleus, suggesting that the first cysteine may function
as a Golgi targeting or retention signal (Fig. 2). Thus, in contrast to
Cdc42 and other RhoGTPases, an intact CAAXmotif is not required for
membrane localization.
TheWrch-1 CAAXmotif contains a second cysteine residue at posi-
tion 255 and is similar to the carboxyl-terminal CCXXmotif present on
proteins modified by geranylgeranyltransferase II (GGTase II). Pres-
ently, all known substrates of GGTase II are members of the Rab small
GTPase family. Thus, we speculated that Wrch-1 may possess an atyp-
ical prenylation signal sequence that is dependent instead on this second
cysteine residue, alone or in combination with the first cysteine. There-
fore, we generated a mutant of this cysteine residue, either alone or
together with mutation of Cys-255. Most surprisingly, both Wrch-1
(C256S, CSFV) andWrch-1 (C255S/C256S, SSFV) weremislocalized to
the cytosol in a pattern similar to that of unprocessed small GTPases
(Fig. 2). However, the CSFV mutant did retain minimal plasma mem-
brane localization. Of particular note, mutation of the second or both
cysteines resulted in nucleoplasm, but not nucleosome, accumulation of
the HA-tagged Wrch-1 protein, implicating a potential nuclear local-
ization signal within the carboxyl terminus of Wrch-1. These results
suggested that Wrch-1 may be prenylated at Cys-256 rather than at
Cys-255 and that, like other Ras and Rho family proteins, additional
sequences within the carboxyl terminus may function as a secondary
membrane targeting signal and/or nuclear localization signal in conju-
gation with modification of these cysteine residues.
Wrch-1 Localization Is Not Dependent on Isoprenoid Modification—The
importance ofCys-256 suggested that perhapsWrch-1 terminates in an atyp-
icalprenylationsignal sequence.Toaddress thispossibility,wefirstdetermined
whether Wrch-1 is a substrate for GGTase I or for FTase. We treated cells
expressingGFP-taggedWrch-1with pharmacological inhibitors of GGTase I
(GGTI) and of FTase (FTI).We have shown previously that inhibition of pre-
nylationofGFP-taggedsmallGTPasesresults innuclearaccumulationbecause
of the lossof themembranetargeting lipidandtothenuclear localizationsignal
present within the GFP protein (20, 25). Therefore, sensitivity of the GFP-
tagged GTPase to drug treatment was measured by redistribution of nuclear
excluded,membrane-bound proteins to the cytosol and nucleus. Efficacy and
specificityofdrugtreatmentwereconfirmedbytheirability tocauserelocaliza-
tion of GFP-tagged H-Ras (farnesylated), Cdc42 (geranylgeranylated), and
K-Ras (alternativelyprenylated)proteins tothenucleusandcytosolupontreat-
ment with FTI, GGTI, and FTI plus GGTI, respectively (Fig. 3). As expected,
FTI treatment caused mislocalization of H-Ras but not K-Ras4B or Cdc42,
whereas GGTI treatment caused mislocalization of Cdc42 but not H-Ras or
K-Ras4B.Mostsurprisingly,Wrch-1 localizationwascompletelyunaffectedby
treatment with either GGTI or FTI (Fig. 3). To eliminate the possibility that
FIGURE 1. The carboxyl-terminal hypervariable domain contributes to differences
in subcellular localization of Cdc42 and Wrch-1. A, sequence alignment of the hyper-
variable domains of Cdc42 and Wrch-1 demonstrates differences in length and compo-
sition. B, Wrch-1 and Cdc42 exhibit distinct subcellular locations. NIH 3T3 fibroblasts
were transiently transfected with pEGFP empty vector or pEGFP constructs encoding
GFP-tagged full-length Cdc42 or Wrch-1, or GFP fused to the carboxyl-terminal nine
residues of Wrch-1, which are sufficient to promote Wrch-1 membrane association. a.a.,
amino acids. C, endosomal localization of Wrch-1. Colocalization of GFP-Wrch-1 (green,
left panel) and the early endosomal marker Texas Red-conjugated transferrin (red, middle
panel) is indicated by the yellow areas in the merged image (right panel). Live cells were
imaged after 24 h. Images are representative of at least three independent experiments.
FIGURE 2. The second cysteine of the Wrch-1 (C)CFV motif is required for Wrch-1
membrane localization. NIH 3T3 cells were transiently transfected with the following
expression constructs: HA-tagged Wrch-1(Q107L)(CCFV) or Wrch-1 bearing carboxyl-
terminal mutations at cysteine residues 255 (CCFV  SCFV), 256 (CCFV  CSFV), or both
(CCFV  SSFV). Cells were fixed and stained with anti-HA primary and FITC-conjugated
anti-mouse secondary antibody. Wrch-1 proteins lacking cysteine 256 (CSFV, SSFV) accu-
mulated in the cytosol. Images are representative of three independent experiments.
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Wrch-1, like K-Ras, is alternatively prenylated by geranylgeranylation when
farnesylation is blocked, cellswere also treatedwith a combinationof bothFTI
andGGTI. AlthoughH-Ras, Cdc42, and K-Ras were all sensitive to the com-
bination treatment,Wrch-1 still did notmislocalize (Fig. 3). These results sug-
gested that, unlikemostRhoproteins,Wrch-1 isnotpost-translationallymod-
ified by either FTase or GGTase I andmay, therefore, be a novel substrate for
prenylation by theRabGGTase,GGTase II.
Wenext evaluatedwhetherWrch-1 is a substrate forGGTase II or for
an unknown prenyltransferase. Because there are currently no pharma-
cological inhibitors available that specifically target GGTase II, we used
compactin to treat NIH 3T3 cells transiently transfected with pEGFP-
Wrch-1, -Rab5, -Cdc42, or empty vector. Compactin, an inhibitor of
hydroxymethylglutaryl-CoA reductase, prevents the formation of all
isoprenoid precursors, thereby preventing the formation of the farnesyl
and geranylgeranyl isoprenoid moieties used by all prenyltransferases,
including GGTase II. Vehicle-treated cells showed nuclear exclusion
and membrane and cytosolic localization of each GFP-tagged GTPase,
as expected (Fig. 4). Compactin treatment caused both Cdc42 and the
GGTase II substrate Rab5 (CAAX  CCSN) to mislocalize to the
nucleus and cytosol (Fig. 4). In contrast,Wrch-1was entirely resistant to
the treatment and remained excluded from the nucleus and targeted to
the membranes and cytosol (Fig. 4). Given that both Rab5 and Cdc42
were susceptible to compactin treatment, these results clearly demon-
strate that Wrch-1 membrane association is not dependent on modifi-
cation with any isoprenoid moiety.
To confirm that Wrch-1 does not utilize isoprenoid lipid groups for
its membrane targeting, we performed in vitro prenylation assays on
purified, un-lipidated Wrch-1 protein to directly label Wrch-1 protein
with either [3H]farnesylpyrophosphate (FPP) or GGPP. Purified bacte-
rially expressed GST-tagged Ras and Rho family proteins are unpreny-
lated because of absence of FTase, GGTase I, or GGTase II enzymes in
E. coli. Purified H-Ras, H-Ras (FTase substrate) CVLLmutant (contains
serine to leucinemutation of the CAAXmotif, GGTase I substrate), and
Rab5 (GGTase II substrate) proteins served as standard controls for
correct incorporation of [3H]FPP and [3H]GGPP by prenyltransferases.
Incubation of purified, bacterially expressed Wrch-1 protein with
bovine brain lysate, containing endogenous FTase, GGTase I, and
GGTase II enzymes, and [3H]prenylpyrophosphates followed by auto-
radiography demonstrated that, unlike H-Ras and Rab5, Wrch-1 was
unable to incorporate [3H]FPP or [3H]GGPP (Fig. 5). To confirm further
the absence of isoprenylmodification of purifiedWrch-1 protein, radio-
activity of each [3H]FPP- or [3H]GGPP-bound protein reaction was
determined by counting in a scintillation counter. As expected, no
radioactivity was detected with Wrch-1, whereas [3H]FPP radioactivity
counts were present for H-Ras WT and [3H]GGPP counts for H-Ras
CVLL and Rab5 WT (data not shown). Taken together with the above
prenyltransferase inhibitor data, these data indicate that, unlike most
Ras and Rho family proteins, Wrch-1 is not a substrate of FTase,
GGTase I, or GGTase II, and its membrane localization is independent
of isoprenylation.
Wrch-1 Subcellular Localization Is Dependent on Palmitoyla-
tion—The data above indicate that, unlike those of Cdc42, the last four
amino acids of Wrch-1 do not function as a canonical “CAAX” motif to
specify prenylation. However, because a carboxyl-terminal cysteine is
clearly important for Wrch-1 localization, we then investigated other
potential post-translational modifications that might occur at cysteine
residues. Palmitoylation is the reversible attachment of a palmitoyl fatty
acid to cysteines via a thioester bond (35, 36). Although no consensus
signal sequence exists to aid in the prediction of which cysteine residues
are likely to be palmitoylated (35, 36), palmitoylation of cysteines in the
hypervariable domains of prenylated small GTPases is common,
although CAAX-signaled prenylation is a critical prerequisite for this
fatty acid modification (18, 26, 37, 38). To determine whether the car-
boxyl-terminal cysteine residues of Wrch-1 are susceptible to thioester
linkage to acyl groups like palmitates, we performed a recently described
nonradioactive method for determining protein acylation (34). This
method utilizes the ability of hydroxylamine to cleave thioester bonds
resulting in free sulfhydryl groups that can then interact with biotin-conju-
gated 1-biotinamido-4-[4-(maleimidomethyl)cyclohexanecarboxamido]
butane (Btn-BMCC) sulfhydryl-specific reagent, effectively labeling acy-
lated cysteine residues. Transiently expressedGFP-taggedWrch-1 protein
immunoprecipitated from human embryonic kidney 293 cells, was sus-
FIGURE 3. Wrch-1 is not prenylated by either FTase or GGTase I. NIH 3T3 cells were
transiently transfected with either empty pEGFP vector or pEGFP constructs encoding
GFP-tagged H-Ras (farnesylated, FTI-sensitive), Cdc42 (geranylgeranylated, GGTI-sensi-
tive), or Wrch-1 in the presence of 10 M vehicle, FTI-2153, GGTI-2166, or a combination
of both, and live cells were imaged 24 h post-transfection. Fully processed GTPases are
excluded from the nucleus, whereas accumulation of GFP-tagged proteins in the
nucleus following treatment with prenyltransferase inhibitors is indicative of unproc-
essed protein. Images are representative of at least three independent experiments.
FIGURE 4. Wrch-1 localization is not dependent on any isoprenoid modification. NIH
3T3 cells transiently expressing either empty pEGFP vector or EGFP constructs encoding
GFP-tagged Cdc42 (geranylgeranylated by GGTase I; compactin-sensitive), Rab5 (gera-
nylgeranylated by GGTase II; compactin-sensitive), or Wrch-1 fusion proteins were
treated overnight with either Me2SO vehicle or 20 M compactin (an inhibitor of all
isoprenoid precursors). As above, mislocalization of GFP-tagged proteins to cytosol and
nucleus after compactin treatment is indicative of disruption of isoprenoid-dependent
localization. Images are representative of at least three independent experiments.
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pended in N-ethylmaleimide to block any free, nonacylated cysteine resi-
dues, treated with hydroxylamine to cleave thioester bonds, and incubated
withBtn-BMCCreagent to labelnewlyexposedsulfhydryl groups, followed
byWestern blot analysis with streptavidin to detect any fatty acid modifi-
cations. Like H-Ras (palmitoylated on Cys-181 and Cys-184), Wrch-1 was
labeled with the Btn-BMCC reagent, suggesting thatWrch-1 contains one
ormore cysteine residues that are acylated (Fig. 6A,Wrch-1CCFV lane, top
band). The nonspecific lower band seen in Fig. 6A, Wrch-1 lanes, is also
observed at the samemolecular weight in theH-Ras lane. As expected, the
Btn-BMCC signal for K-Ras4B (no palmitoylated cysteines) was notably
absent (Fig. 6A).
BecauseWrch-1 contains two cysteine residues at its carboxyl termi-
nus that may be palmitoylated, we wanted to determine whether one or
both cysteine residues were susceptible to acylation. We anticipated
that the second cysteine, Cys-256, would be the preferred site for acy-
lation because of the cytosolic and nuclear subcellular distributionwhen
mutated to a serine residue (CSFV). However, the CSFV mutant did
retain some membrane localization, and it is possible that the first cys-
teine (Cys-255) may also be lipid-modified. As seen with parental
Wrch-1 (CCFV), Wrch-1 (C255S, SCFV) labeled with Btn-BMCC,
albeit at a lower efficiency, suggesting that the first cysteine residue
(Cys-255) may regulate acylation of the second cysteine (Cys-256) (Fig.
6A, Wrch-1 SCFV lane, top band). As expected, neither the Wrch-1
(C256S, CSFV) nor (C255S/C256S, SSFV) mutants were labeled with
Btn-BMCC (Fig. 6A, Wrch-1 CSFV, -SSFV lanes, top band). Addition-
ally, treatment of Wrch-1 with the palmitate analog 2-BP, a potent
inhibitor of small GTPase palmitoylation (37), caused a dramatic
decrease in Wrch-1 fatty acid modification, suggesting that palmitate
lipids are the fatty acid moieties utilized byWrch-1 (Fig. 6B, top panel).
Expression of each protein was confirmed byWestern blot analysis (Fig.
6A, bottom panel). These results indicate that the second cysteine resi-
due of Wrch-1 (Cys-256) is the primary cysteine residue for palmitate
fatty acid modification.
To investigate directly whether the fatty acidmodification ofWrch-1
detected by the above Btn-BMCC method is due to incorporation of
palmitoyl groups at its carboxyl-terminal cysteines, similar toH-Ras, we
used [3H]palmitate to metabolically label NIH 3T3 cells transiently
expressing Wrch-1 (38). Correct incorporation of [3H]palmitate was
confirmed using cells expressing H-Ras (palmitoylated on Cys-181 and
Cys-184) and K-Ras (no palmitoylatable cysteines) as positive and neg-
ative controls, respectively. Immunoprecipitation of the exogenous
HA-tagged Wrch-1 protein from labeled cells, followed by autoradiog-
raphy, showed that Wrch-1, like H-Ras, incorporated [3H]palmitate
(Fig. 6C, top panel). The reduced level of incorporation seen inWrch-1
compared with H-Ras may be due in part to potential differences in
palmitoyl turnover and, therefore, steady-state levels of the palmitoy-
latedGTPases and in part to the single palmitoylated cysteine residue in
Wrch-1 compared with the two palmitoylatable cysteines in H-Ras.
Western blot analysis of the total lysate input and immunoprecipitated
K-Ras4B protein confirm that the absence of a [3H]palmitate signal in
the K-Ras-expressing cells was not due simply to a lack of protein
expression or immunoprecipitation (Fig. 6C, middle and bottom
panel). These results directly demonstrate that Wrch-1 is modified by
palmitoylation.
Next, we investigatedwhether one or bothWrch-1 carboxyl-terminal
cysteine residues are substrates for palmitoylation. Given that the
Wrch-1 (C255S, SCFV) mutant, but not the Wrch-1 (C256S, CSFV) or
-(C255S/C256S, SSFV) mutants, retained an acylated cysteine residue,
we anticipated the second cysteinewould also prove to be the important
cysteine residue for palmitoylation. Like the Wrch-1 (CCFV) parent,
Wrch-1 (C255S, SCFV) mutant incorporated the [3H]palmitate signal,
whereas Wrch-1 (C255S, CSFV)- and -(C255S/C256S, SSFV)-express-
ing cells lacked a [3H]palmitate and, therefore, failed to incorporate
[3H]palmitate (Fig. 6D, top panel). Expression of each protein is con-
firmed by Western blot analysis of total lysate input and immunopre-
cipitated CSFV and SSFV protein (Fig. 6D, middle and bottom panels).
These data show that the second cysteine residue is the required cys-
teine for palmitoylation. Thus, as with other palmitoylated small
GTPases, this post-translational modification may be important for
Wrch-1 subcellular localization.
To determine whether palmitoylation influences Wrch-1 localiza-
tion, we treated NIH 3T3 cells transiently expressing GFP-tagged
Wrch-1,H-Ras, K-Ras, or empty vectorwith 2-BP. 2-BP has been shown
previously to cause the redistribution of palmitoylated GTPases, most
recently the Cdc42 homologous protein Chp/Wrch-2, and other pro-
teins within the cell (18, 37, 39). As expected, the lack of palmitoylatable
sites within theK-Ras carboxyl terminus rendered its localization insen-
sitive to the effects of 2-BP, whereas H-Ras was mislocalized from
plasma membrane to endomembranes, thereby demonstrating sub-
strate specificity of 2-BP for carboxyl-terminal cysteine-containing pro-
teins (Fig. 7). Upon treatment with 2-BP, GFP-Wrch-1 relocalized dra-
matically to the cytosol and accumulated in the nucleus (Fig. 7). That
Wrch-1 localization is sensitive to 2-BP treatment is consistent with our
Btn-BMCC and metabolic labeling studies showing that Wrch-1 is
palmitoylated. These results suggest that palmitate(s) could be the sole
lipid modification normally causing retention of Wrch-1 in the cytosol
and membranes.
The Carboxyl-terminal Cysteines Are Necessary for Wrch-1 Signaling
to PAK—Because inhibition of palmitoylation and mutation of the car-
boxyl-terminal cysteines to serines rendered Wrch-1 improperly dis-
tributed, we predicted that loss of the palmitatemodificationwould also
affect Wrch-1 downstream signaling pathways. Previous studies have
shown that activated, constitutively GTP-bound Wrch-1 results in
increased auto-phosphorylation of the serine/threonine kinase PAK
(15, 16). PAK1 is a well known effector of several Rho family proteins,
including Cdc42 and Rac (3). To determine whether mutation of the
carboxyl-terminal cysteines of Wrch-1 would affect its ability to pro-
mote auto-phosphorylation of PAK in NIH 3T3 fibroblasts, we tran-
siently expressed the cysteine to serine mutants in an activated
FIGURE 5. Wrch-1 does not incorporate isoprenoid moieties. Recombinant, purified
H-Ras (FTase substrate), H-Ras CVLL mutant (GGTase I substrate), Rab5 WT (GGTase II
substrate), and Wrch-1 proteins were incubated in reaction mixture with bovine brain
lysate containing endogenous prenyltransferase activity and [3H]farnesylpyrophos-
phate (FPP) or [3H]geranylgeranylpyrophosphate (GGPP). To detect incorporation of
radioactive prenylpyrophosphates, reactions were then analyzed by SDS-PAGE and
autoradiography. The presence of a band demonstrates incorporation of indicated iso-
prenyl groups.
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Wrch-1(Q107L) background and looked for differences in the PAK
phosphorylation status. As shown previously by us and others (15, 16),
the Wrch-1(Q107L) CCFV parent resulted in an increase in phospho-
rylated PAK levels when compared with vector-expressing cells (Fig. 8).
Consistent with the loss of membrane association, the ability of the
Wrch-1 SCFV, -CSFV, and SSFVmutants to induce phosphorylation of
PAK was considerably reduced when compared with the CCFV parent.
This suggests that correct localization ofWrch-1 via its palmitate mod-
ification is necessary for downstream signaling molecules.
The Carboxyl-terminal Cysteine 256 (CCFV), but Not 255 (CCFV), Is
Required for Wrch-1 Transformation—Given that loss of palmitate
modification affectedWrch-1 downstream signaling, we predicted that
loss of the palmitate modification would also affect Wrch-1 biological
activity. The transforming activity of prenylated Rho family proteins is
impaired when palmitate modification is blocked (25). We sought to
determine whether loss of palmitoylation would interfere with Wrch-1
transformation.
Previous studies showed that activated Raf can cooperate with con-
stitutively activated Rho family members such as Cdc42 to cause syner-
gistic transformation of NIH 3T3 cells (40–43). To determine whether
Wrch-1, like Cdc42, could also cooperate with Raf to cause focus for-
mation, we transiently cotransfected into NIH 3T3 cells pCGN-hygro
constructs expressing activated Wrch-1(Q107L), Cdc42(Q61L), or
Rac1(Q61L), together with either pZIP-Raf22W or the empty pZIP-
NeoSV(x)1 vector. We then evaluated the dishes for the appearance of
foci of transformed cells. Raf-induced foci of transformed cells are indis-
tinguishable in appearance from those caused by activated Ras and are
characterized by large, spreading foci of highly refractile, spindle-
shaped, morphologically transformed cells. In contrast, activated Rho
GTPases cause foci of transformed cells that are very distinct from those
of Raf, and are characterized by tight clusters of rounded, refractile cells
that are frequently multinucleated. We anticipated that the appearance
ofWrch-1 focimight resemble those of Cdc42more than those of Raf-1.
As expected, activatedWrch-1 alone was unable to induce focus forma-
tion (Fig. 9A). In cooperation with Raf, however, activated Wrch-1
formed foci that were similar to those of Cdc42 and Rac1 (Fig. 9A).
Next, we evaluated whether loss of the carboxyl-terminal cysteines,
individually or together, impaired Wrch-1 focus formation in coopera-
tion with Raf. The ability of activatedWrch-1-CSFV and -SSFV to form
foci of transformed cells was greatly reduced compared with that of the
parental Wrch-1 (Fig. 9B). These results are consistent with a critical
role for the second cysteine (CCFV), rather than the canonical CAAX
FIGURE 6. Wrch-1 is palmitoylated. NIH 3T3 cells were transiently transfected with either pEGFP constructs encoding GFP-tagged (A and B) or pCGN constructs encoding HA-tagged
(C and D) H-Ras (palmitoylated positive control), K-Ras (nonpalmitoylated negative control), or Wrch-1 (CCFV, SCFV, CSFV, and SSFV). Two days post-transfection, proteins were
immunoprecipitated with anti-GFP antibody, treated with hydroxylamine, and labeled with biotin-BMCC to detect acylated cysteine residues (A). A band indicates fatty acid
modification (top panel). Bottom panel detects amount of protein available for immunoprecipitation (IP). WB, Western blot. B, Wrch-1-expressing cells were treated with either Me2SO
vehicle or 150 M 2-BP 12 h prior to immunoprecipitation for Btn-BMCC labeling. C and D, cells were labeled metabolically with a 4-h pulse of [3H]palmitate, and the GTPases were
immunoprecipitated with anti-HA antibody. Immunoprecipitates were subjected to SDS-PAGE and exposed to film for 4 – 6 weeks. Top panel, [3H]palmitate autoradiogram shows
that Wrch-1- and H-Ras-positive control, but not K-Ras4B-negative control, incorporated [3H]palmitate (C). Mutation of carboxyl-terminal cysteines affects Wrch-1 incorporation of
[3H]palmitate (D). Middle panel, to detect total amount of GTPases retrieved for autoradiography, immunoprecipitates were probed for GTPases by Western blot using anti-HA
antibody (IP). Bottom panel, to detect amount of starting protein available for immunoprecipitation (input), total cell lysates were probed by Western blot using anti-HA antibody.
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cysteine (CCFV), in mediating Wrch-1 membrane association. Most
unexpectedly, mutation of the first cysteine residue, SCFV, did not
impairWrch-1 focus forming ability but rather enhanced it. This result
suggests that the roles of the two cysteines are distinct and that the
upstream cysteine plays a negative regulatory role in Wrch-1 biological
activity.
To determine whether these results also applied to other aspects of
the transformed phenotype, we evaluated the ability of activated
Wrch-1 carboxyl-terminal mutants to promote anchorage-independ-
ent growth in soft agar. In contrast to their activity in focus formation
assays, Rho proteins alone, includingWrch-1 (16), are sufficient to con-
fer anchorage-independent growth and do not require cooperationwith
Raf in soft agar assays. Therefore, NIH 3T3 cells stably expressing acti-
vated, HA-tagged Wrch-1(Q107L) were seeded into agar and analyzed
for colony forming activity. Comparable expression of each Wrch-1
protein was seen (data not shown). ActivatedWrch-1 potently induced
colony formation in soft agar (Fig. 9,C andD). Consistent with the focus
formation data, mutation of either the second cysteine (C256S, CSFV)
or both cysteines (C255S/C256S, SSFV) resulted in a strong reduction of
colony formation, whereas the cysteine to serine mutation at residue
255 (SCFV) led to a significant increase in Wrch-1-induced colony for-
mation (Fig. 9, C and D). Taken together, our focus formation and soft
agar analyses suggest that the second cysteine residue of the CCFV
motif is required for Wrch-1 transforming activity, whereas the first
cysteine may function instead as a negative regulator.
DISCUSSION
Wrch-1 gene expression is up-regulated inWnt-1-transformed cells,
andWrch-1 activation can phenocopy the changes in cellular morphol-
ogy caused by Wnt-1 (15). Wrch-1 shares significant amino acid
sequence and functional identity with Cdc42 but exhibits significant
divergence in carboxyl-terminal sequences. Wrch-1 terminates in an
atypical CAAX tetrapeptide motif, and its hypervariable domain pos-
sesses an additional 21 amino acid residues not found in Cdc42. In the
present study, we evaluated the role of these unique carboxyl-terminal
features in Wrch-1 membrane association and biological activity.
Although we found that the carboxyl-terminal nine residues ofWrch-1
alone were sufficient to promote Wrch-1 membrane association,
Wrch-1 and Cdc42 exhibited very distinct patterns of subcellular local-
ization, with significant amounts of Wrch-1 found at the plasma mem-
brane and early endosomes. Most surprisingly, we found that an intact
CAAX motif was not required for Wrch-1 membrane association, but
instead, mutation of a second carboxyl-terminal cysteine significantly
reduced Wrch-1 membrane association. Furthermore, Wrch-1 mem-
brane association was not dependent on isoprenoid modification but
was instead dependent on palmitoylation of the second cysteine residue.
Finally, we found that Wrch-1, like Cdc42, can also promote growth
transformation ofNIH3T3 cells and that the palmitoylated cysteinewas
critical for this activity.
Highly related Rho and Ras GTPases exhibit distinct cellular func-
tions that can be attributed in part to subcellular localizations dictated
by their distinct hypervariable domains (22, 27, 28). For example, RhoA
shares 90% identity with RhoB andRhoC, and these three proteins share
common regulators and effectors (3). However, despite these strong
similarities, whereas RhoA can promote growth transformation, there is
evidence that RhoB may function in an opposite fashion and exhibit
tumor suppressor function (20, 44). RhoC but not RhoA has been asso-
ciated with tumor cell invasion (45, 46). These three related Rho
GTPases show the greatest sequence divergence in their carboxyl-ter-
minal sequences, and this divergence results in differences in subcellular
localization that in turn promote different cellular functions (22, 27, 28).
Philips and co-workers (18) eloquently demonstrated that the last 20
amino acids of several Rho and Ras proteins, including Cdc42, mimic
the subcellular localization of the full-length proteins. We have shown
here that at least the last 9 amino acids ofWrch-1 are sufficient to confer
proper subcellular distribution. This finding is consistent with other
studies that illustrate that all of the membrane targeting information is
located in the carboxyl terminus.
Thus, although Wrch-1 and Cdc42 share significant sequence iden-
tity and functional overlap, their divergent carboxyl-terminal sequences
may also impart different biological roles to these biochemically related
proteins.Mutation of the cysteine residue of the CAAXmotifs of Cdc42
and other Rho GTPases to prevent prenylation results in loss of mem-
brane association and biological activity (20–24). Therefore, we were
surprised that the analogous mutation of the Wrch-1 CAAX motif
(C255S, SCFV) did not cause complete mislocalization or loss of trans-
forming activity. Analogously to Ras family GTPases, the membrane
localization of conventional Rho family proteins generally requires
either a geranylgeranyl (e.g. Cdc42) or a farnesyl lipid group (e.g. Rnd3/
RhoE) attached to the cysteine residue of the CAAXmotif and a “second
FIGURE 7. Palmitate analog 2-BP causes mislocalization and cytosolic accumulation
of Wrch-1. NIH 3T3 cells were transiently transfected with pEGFP empty vector or pEGFP
constructs encoding GFP-tagged K-Ras4B (nonpalmitoylated negative control), H-Ras
(palmitoylated positive control), or Wrch-1. Cells were treated overnight with either
Me2SO vehicle or 150 M 2-BP. The following day, 2-BP-treated cells were assessed for
cytosolic and/or nuclear accumulation by live cell imaging. Images are representative of
at least three independent experiments.
FIGURE 8. Carboxyl-terminal cysteines regulate Wrch-1 downstream signaling to
PAK. NIH 3T3 cells were transiently transfected with pCGN constructs encoding acti-
vated Wrch-1(Q107L) and Wrch-1(Q107L) carboxyl-terminal mutants (SCFV, CSFV, and
SSFV). Whole cell lysates were collected 24 h post-transfection and analyzed by Western
blot for changes in endogenous phosphorylated PAK status (top panel). For controls,
total PAK and HA-Wrch-1 protein levels were analyzed (middle, bottom panels). Blots are
representative of three separate experiments.
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signal” consisting of either several basic residues or palmitoylated cys-
teine residues in the upstream hypervariable domain (3). In direct con-
trast, we show here that the Cdc42 homolog Wrch-1 does not utilize
either a geranylgeranyl or farnesyl isoprenoid moiety for membrane
targeting. Instead, its localization is regulated by a palmitoyl fatty acid,
demonstrating that the Wrch-1 CAAX-like motif, CCFV, is not a
canonical, prenylated CAAX.
It is unclear at this juncture whether Wrch-1 also requires a second
signal for proper localization to plasma membranes. However, the car-
boxyl terminus of Wrch-1 contains several basic residues that could
form a polybasic second signal to complement the palmitate modifica-
tion (47, 48), and are included in the short stretch of nine amino acids
that constitutes a minimal targeting sequence. Alternatively, by analogy
to CAAX-containing palmitoylatable small GTPases, Wrch-1 may
require other poorly defined but essential motifs surrounding palmitoy-
latable cysteines (38, 49). The Wrch-1 carboxyl terminus also contains
uncommon but conserved residues such as tandem tryptophans and a
tyrosine. The tandem tryptophan residues may represent a di-aromatic
motif of the kind frequently associated with endosomal sorting (50) and
may help to direct Wrch-1 to endosomes. The contribution of these
residues toWrch-1membrane targeting and function is currently under
investigation.
More distantly related Rho and Ras proteins also target to mem-
branes but do not depend on carboxyl-terminal lipid modification. For
example, the Rho-related proteins, RhoBTB-1/2 and Miro-1/2, as well
as the Ras-related proteins, Rit, Rin, Gem, and Rem2, are not known to
undergo lipid modification, yet display distinct membrane associations
(29, 51–53). Conversely, although Rab proteins are prenylated, they lack
a conventional CAAXmotif and, instead, terminate in CCXX, CXC, and
XXCC sequences that, in combination with upstream residues, serve as
targeting motifs for GGTase II modification (54, 55). We have demon-
strated here that the CCXXmotif of Wrch-1 is not a target for GGTase
II but rather for palmitoylation. Most interestingly, Chp/Wrch-2, the
closest relative of Wrch-1, lacks a CAAX motif and should, therefore,
not be modified by prenyltransferases (56). However, it shares with
Wrch-1 a CFV (CXX) motif, incorporates a fatty acidmodification at its
carboxyl-terminal cysteine residue, and Chp membrane association is
also disrupted by 2-BP treatment (39). It is interesting to speculate that
the CFV (CXX) motif may be a novel recognition site for post-transla-
tional modification by palmitoyltransferases. Although other mamma-
lian RhoGTPases are also palmitoylated, their palmitatemodification is
dependent on prior modification by prenylation. Therefore, Wrch-1
and Chp undergo unique lipid modification-dependent membrane tar-
geting not seen with other known mammalian Ras family GTPases.
Most interestingly, atypical Rho-like proteins have been described in the
plant Arabidopsis that also undergo a prenyl-independent, palmitoyl
modification; however, these small GTPases terminate neither in con-
ventional CAAX nor in CXXmotifs (57, 58). In addition, their carboxyl-
terminal sequences lack the basic residues found in Wrch-1 and Chp,
and multiple palmitoylated cysteines appear to be required for full
membrane association.
Our finding that the Wrch-1 carboxyl-terminal Cys to Ser mutants
have differential effects onWrch-1 localization and function is unusual
for small GTPases and suggests that each cysteine has a distinct contri-
FIGURE 9. Carboxyl-terminal cysteines of the
hypervariable domain differentially modulate
Wrch-1 transforming activity. NIH 3T3 cells were
transiently cotransfected with either empty vector
pZIPneo or activated pZIP-Raf22W, along with
pCGN constructs encoding activated Rac1(Q61L),
Cdc42(Q61L), or Wrch-1(Q107L). After 14 days,
dishes were fixed and stained with crystal violet,
and foci of transformed cells were counted.
Images are representative of at least three sepa-
rate experiments carried out in duplicate. A, acti-
vated Wrch-1 cooperates with activated Raf to
form Cdc42-like foci of transformed cells. B, coop-
eration with Raf by Wrch-1 containing carboxyl-
terminal mutations at cysteine residues 255
(CCFV  SCFV), 256 (CCFV  CSFV), or both
(CCFV  SSFV). C, NIH 3T3 cells stably expressing
the above-mentioned pCGN Wrch-1 constructs
were seeded into soft agar and analyzed for their
ability to induce anchorage-independent growth.
Colonies formed after 14 –21 days were stained
and scanned (D) and quantified (C). Images and bar
graphs are representative of at least two separate
experiments carried out in triplicate.
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bution to Wrch-1 function. Consistent with this possibility, we have
shown that mutation of Cys-255 (SCFV) resulted in increased trans-
forming activity of Wrch-1, suggesting that this residue has a negative
regulatory effect on Wrch-1 localization and function, whereas muta-
tion of Cys-256 (CSFV) abrogated membrane localization and transfor-
mation. Most interestingly, we have made a similar observation with
Chp, where mutation of the cysteine residue of the CFV motif caused
mislocalization and loss of transforming activity, whereas mutation of
an upstream cysteine did not alter membrane association, yet caused a
significant enhancement of transforming activity (39). It is formally pos-
sible that one cysteine regulates acylation of the second cysteine; more
sensitive methods for detection of such modifications will be necessary
to determine whether this is the case.
Palmitoylation of cysteines in the hypervariable domain of Wrch-1
suggests thatWrch-1may traffic and signal similarly to other palmitate-
containing small GTPases such as H-Ras and TC10 rather than Cdc42.
For example, palmitoylated H-Ras, but not polybasic domain-contain-
ing K-Ras, transports to the plasma membrane via a Golgi-mediated
process leading to the association of H-Ras with cholesterol-rich lipid
rafts (59–61). Lipid rafts are specialized microdomains that contain
distinct composition of lipids and signaling proteins that may organize
signals impinging on the cell surface into distinct cascades (62). For
some palmitoylated small Rho GTPases, such as TC10, lipid raft local-
ization is critical to their downstream activity. For example, one study
showed that TC10 could control Glut 4 activity only if specifically tar-
geted to lipid rafts (63). TC10 has two nontandem upstream cysteines
that are substrates for palmitoylation. Mutation of the cysteine imme-
diately upstream of the CAAX motif prevented endomembrane local-
ization of TC10, whereas the other cysteine had no effect on TC10
subcellular distribution (64). Because palmitoylation favors association
of proteins to lipid rafts, it is possible that Wrch-1 may also traffic
through the exocytic pathway to interact with these lipid-richmicrodo-
mains, thereby introducing different Wrch-1 protein-protein interac-
tions that Cdc42, lacking a palmitoylation site, may not encounter.
These differences in subcellular localization suggest a potential mecha-
nism for functional diversity.
Palmitoylation of Wrch-1 may also provide another level of regula-
tion for Wrch-1 protein interactions and biological function. Rho and
Ras protein activities are regulated by both nucleotide binding and sub-
cellular location. For example, RhoGDIs negatively regulate Cdc42 and
other Rho family proteins by binding their prenoidmoieties and seques-
tering the proteins to the cytosol (9, 10). BecauseWrch-1 lacks a prenyl
group and does not bind RhoGDIs,5 the dynamic, reversible nature of
palmitoylation could serve instead as a “RhoGDI-like” regulatory entity
forWrch-1 localization. The turnover rate for H-Ras palmitoylation is a
rapid (t1⁄2 20min) (65, 66), andH-Ras lacking palmitoylatable cysteines
fails to target the plasmamembrane and is functionally deficient (26, 38,
66). Most recently, a de/reacylation cycle on H-Ras has been shown to
regulate its localization and activation subcellularly (67). Palmitoylation
targets H-Ras not only to the plasma membrane but specifically to lipid
rafts where dynamic GTP-dependent shifts of H-Ras in and out of rafts
occur (68). Similar palmitoylation and de-palmitoylation kinetics for
Wrch-1 palmitoylation could similarly cause Wrch-1 to quickly enter
and exit lipid rafts and regulate Wrch-1 downstream activity in a
dynamic manner. Our recent data demonstrate thatWrch-1 exchanges
GDP unusually rapidly (69). Thus, rapid movement of Wrch-1 in and
out of lipid rafts may combine with the fast-cycling nature of Wrch-1,
leading to regulatory control ofWrch-1 based in part on its localization.
To date, there are no published human protein S-acyltransferases
(PATs) shown tomodifyWrch-1 or other palmitoylated small GTPases.
However, recent yeast genetic screens for PAT components have iden-
tified PAT genes that are necessary for palmitoylation of yeast Ras (70).
These yeast PAT genes contain a cysteine-rich domain and a DHHC
motif required for PAT activity, and this DHHC-cysteine-rich domain
motif has been found in several human proteins that are involved in the
S-acylation of specific neuronal proteins (70–73). Given that there are
several DHHC-cysteine-rich domain-containing genes, characteriza-
tion of these genes as PATs could reveal potential regulatory proteins
for Wrch-1 localization and, ultimately, its downstream activity and
serve as potential targets for pharmacological inhibitors.
Because Cdc42 and other Rho GTPases have been implicated in
human oncogenesis (11–14), inhibitors of GGTase I have been consid-
ered for cancer therapy (31, 74). However, because Cdc42 function is
important for normal cell proliferation, one concern is that GGTIs may
exhibit significant normal cell toxicity. BecauseWrch-1 andChp exhibit
functional overlap with Cdc42, and their functions are not dependent
on GGTase I activity, perhaps these atypical Rho GTPases will provide
some protection against GGTase I suppression of Cdc42 function in
normal cells.
In summary, our recent delineation of a unique regulatory function of
the amino terminus ofWrch-1 (69) together with the unusual nature of
the Wrch-1 carboxyl terminus in mediating subcellular localization
identified in this study make Wrch-1 highly distinct from the classical
Rho familyGTPases.Wrch-1 togetherwithChp represent a new class of
mammalian Rho GTPases whose membrane targeting and biological
activity are dependent on lipidation by palmitoyl fatty acids but not by
isoprenoids. Our studies with structural mutants suggest distinct func-
tional contributions of palmitoylation at different carboxyl-terminal
cysteines. Further studies are needed to determine how the other resi-
dues of the hypervariable domain affect Wrch-1 localization and func-
tion. Additional studies of Wrch-1 and other palmitoylation-only lipi-
dated small GTPases like Chp/Wrch-2 and Arabidopsis Rac proteins
will also be necessary to clarify how thismodification affects their ability
to localize and to target downstream signaling pathways. The novel
mechanism by whichWrch-1 and Chp function is regulated by carbox-
yl-terminal sequences and lipid modifications adds further to the com-
plexity by which carboxyl-terminal variation may diversify the biologi-
cal roles of proteins that otherwise exhibit strong biochemical
similarity.
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